{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T07:01:01Z","timestamp":1771225261941,"version":"3.50.1"},"reference-count":27,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T00:00:00Z","timestamp":1756339200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"},{"start":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T00:00:00Z","timestamp":1756339200000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Cathet Cardio Intervent"],"published-print":{"date-parts":[[2025,10]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>DESyne BDS Plus represents a novel triple drug therapy (TRx) applied on a coronary stent platform eluting the antiproliferative drug Sirolimus along with two anticoagulants (Rivaroxaban and Argatroban) to reduce the site\u2010specific thrombotic risk.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Aims<\/jats:title>\n                    <jats:p>To assess the feasibility and safety of this novel device against a contemporary drug\u2010eluting stent.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This prospective, multicenter randomized (1:1) trial included 202 patients assigned between the device group (DESyne BDS Plus) and the control group (DESyne X2). A subgroup of 58 patients underwent imaging follow\u2010up at 6 months. The blood pharmacokinetics of Sirolimus and both anticoagulants were assessed in 11 nonrandomized patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      The primary endpoint, target lesion failure (TLF) at discharge or 3\u2010day postprocedure, whichever occurred first, was 0.0% (0\/98) in the device and 5.0% (5\/100) in the control group (\n                      <jats:italic>p<\/jats:italic>\n                      <jats:sub>noninferiority<\/jats:sub>\n                      \u2009&lt;\u20090.001). The secondary endpoint, late lumen loss at 6 months, was 0.14\u2009mm [90% CI: 0.06; 0.23] and 0.09\u2009mm [90% CI: 0.01; 0.18] in the device (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200928) and control group (\n                      <jats:italic>n<\/jats:italic>\n                      \u2009=\u200927), respectively (\n                      <jats:italic>p<\/jats:italic>\n                      <jats:sub>noninferiority<\/jats:sub>\n                      \u2009&lt;\u20090.001). Through 24 months, stent thrombosis (definite\/probable) was 0.0% (0\/97) versus 1.0% (1\/96) in the control,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.497, and TLF was 2.1% (2\/97) versus 11.3% (11\/97),\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.010, respectively. Optical coherence tomography findings including strut coverage and neointimal hyperplasia thickness\/volume were similar between the groups. The pharmacokinetic study indicated median maximum blood concentrations (C\n                      <jats:sub>max<\/jats:sub>\n                      ) of Rivaroxaban and Argatroban of 1.38\u2009ng\/mL and 1.99\u2009ng\/mL, respectively.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This is the first clinical evidence of the feasibility of site\u2010specific antithrombotic therapeutic with two anticoagulants and an antiproliferative mTOR inhibitor.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/ccd.70106","type":"journal-article","created":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T07:06:52Z","timestamp":1756364812000},"page":"2770-2780","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Site\u2010Specific Antithrombotic Therapy: 24\u2010Month Outcomes of the Randomized DESyne BDS Plus Trial Using a Novel Triple\u2010Drug Eluting Coronary Implant With Two Anticoagulants and Sirolimus"],"prefix":"10.1002","volume":"106","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2182-1065","authenticated-orcid":false,"given":"Stefan","family":"Verheye","sequence":"first","affiliation":[{"name":"Interventional Cardiology ZAS Cardiovascular Center Middelheim Antwerp Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bert","family":"Ferdinande","sequence":"additional","affiliation":[{"name":"Department of Cardiology Ziekenhuis Oost\u2010Limburg, Campus Sint Jan Genk Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8301-4517","authenticated-orcid":false,"given":"Johan","family":"Bennett","sequence":"additional","affiliation":[{"name":"Department of Cardiovascular Medicine Universitaire Ziekenhuizen Leuven Leuven Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rodolfo","family":"Staico","sequence":"additional","affiliation":[{"name":"Instituto Dante Pazzanese S\u00e3o Paulo Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seif","family":"El\u2010Jack","sequence":"additional","affiliation":[{"name":"Cardiovascular Unit North Shore Hospital Auckland New Zealand"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pim A. L.","family":"Tonino","sequence":"additional","affiliation":[{"name":"Heart Center Catharina Hospital Eindhoven the Netherlands"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexandre","family":"Abizaid","sequence":"additional","affiliation":[{"name":"Instituto do Cora\u00e7\u00e3o S\u00e3o Paulo Brazil"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ian","family":"Buysschaert","sequence":"additional","affiliation":[{"name":"Interventional Cardiology AZ Sint Jan Brugge AV Bruges Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Douglas","family":"Scott","sequence":"additional","affiliation":[{"name":"Department of Cardiology Middlemore Hospital Auckland New Zealand"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Madhav","family":"Menon","sequence":"additional","affiliation":[{"name":"Department of Cardiology Waikato Hospital Hamilton New Zealand"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gerard","family":"Wilkins","sequence":"additional","affiliation":[{"name":"Cardiology Department Dunedin Hospital Dunedin New Zealand"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dougal","family":"McClean","sequence":"additional","affiliation":[{"name":"Cardiology Department Christchurch Hospital Christchurch New Zealand"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tomas","family":"Kovarnik","sequence":"additional","affiliation":[{"name":"2nd Department of Medicine \u2010 Department of Cardiovascular Medicine, First Faculty of Medicine General University Hospital in Prague, Charles University Prague Czech Republic"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Uwe","family":"Christians","sequence":"additional","affiliation":[{"name":"iC42 Integrated Solutions in Systems Biology for Clinical Research &amp; Development University of Colorado Aurora Colorado USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antoinette","family":"Neylon","sequence":"additional","affiliation":[{"name":"CERC (Cardiovascular European Research Center) Massy France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zlatko","family":"Mehmedbegovic","sequence":"additional","affiliation":[{"name":"CERC (Cardiovascular European Research Center) Massy France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Pieter C.","family":"Smits","sequence":"additional","affiliation":[{"name":"CERC (Cardiovascular European Research Center) Massy France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marie\u2010Claude","family":"Morice","sequence":"additional","affiliation":[{"name":"CERC (Cardiovascular European Research Center) Massy France"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7661-7694","authenticated-orcid":false,"given":"Mark","family":"Webster","sequence":"additional","affiliation":[{"name":"Cardiac Investigation Unit Auckland City Hospital Auckland New Zealand"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"the DESyne BDS Plus RCT Investigators","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2025,8,28]]},"reference":[{"key":"e_1_2_9_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2021.09.005"},{"key":"e_1_2_9_3_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.117.028885"},{"key":"e_1_2_9_4_1","doi-asserted-by":"publisher","DOI":"10.1002\/ccd.30783"},{"key":"e_1_2_9_5_1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehv203"},{"key":"e_1_2_9_6_1","doi-asserted-by":"publisher","DOI":"10.4244\/EIJY19M01_01"},{"key":"e_1_2_9_7_1","doi-asserted-by":"publisher","DOI":"10.3390\/jcm12031238"},{"key":"e_1_2_9_8_1","doi-asserted-by":"publisher","DOI":"10.4244\/EIJ-D-21-00904"},{"key":"e_1_2_9_9_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40262-013-0100-7"},{"key":"e_1_2_9_10_1","doi-asserted-by":"publisher","DOI":"10.1517\/17425255.2012.722621"},{"key":"e_1_2_9_11_1","doi-asserted-by":"publisher","DOI":"10.4244\/EIJY15M10_04"},{"key":"e_1_2_9_12_1","doi-asserted-by":"publisher","DOI":"10.1002\/clc.24317"},{"key":"e_1_2_9_13_1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehy223"},{"key":"e_1_2_9_14_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1004130"},{"key":"e_1_2_9_15_1","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.120.019815"},{"key":"e_1_2_9_16_1","doi-asserted-by":"publisher","DOI":"10.1002\/ccd.30902"},{"key":"e_1_2_9_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.carrev.2014.07.002"},{"key":"e_1_2_9_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0735-1097(98)00289-7"},{"key":"e_1_2_9_19_1","doi-asserted-by":"publisher","DOI":"10.1160\/TH15-01-0061"},{"key":"e_1_2_9_20_1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehad191"},{"key":"e_1_2_9_21_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijcard.2010.02.044"},{"key":"e_1_2_9_22_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1538-7836.2003.00298.x"},{"key":"e_1_2_9_23_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1538-7836.2005.01166.x"},{"key":"e_1_2_9_24_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra044440"},{"key":"e_1_2_9_25_1","doi-asserted-by":"publisher","DOI":"10.1592\/phco.20.4.318.34881"},{"key":"e_1_2_9_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcin.2025.01.426"},{"key":"e_1_2_9_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2023.102304"},{"key":"e_1_2_9_28_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCINTERVENTIONS.114.001441"}],"container-title":["Catheterization and Cardiovascular Interventions"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ccd.70106","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/ccd.70106","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/ccd.70106","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,16]],"date-time":"2026-02-16T06:01:33Z","timestamp":1771221693000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/ccd.70106"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,28]]},"references-count":27,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,10]]}},"alternative-id":["10.1002\/ccd.70106"],"URL":"https:\/\/doi.org\/10.1002\/ccd.70106","archive":["Portico"],"relation":{},"ISSN":["1522-1946","1522-726X"],"issn-type":[{"value":"1522-1946","type":"print"},{"value":"1522-726X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,28]]},"assertion":[{"value":"2025-07-31","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-08-16","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-08-28","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}